Shanghai Rightongene Biotechnology Co., Ltd. (SHA:688217)
China · Delayed Price · Currency is CNY 31.11
-0.15 (-0.48%)
At close: Feb 13, 2026
SHA:688217 Revenue
Shanghai Rightongene Biotechnology had revenue of 34.36M CNY in the quarter ending September 30, 2025, a decrease of -51.34%. This brings the company's revenue in the last twelve months to 191.78M, down -22.99% year-over-year. In the year 2024, Shanghai Rightongene Biotechnology had annual revenue of 242.31M, down -6.16%.
Revenue (ttm)
191.78M
Revenue Growth
-22.99%
P/S Ratio
8.95
Revenue / Employee
478.25K
Employees
385
Market Cap
1.72B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 242.31M | -15.91M | -6.16% |
| Dec 31, 2023 | 258.21M | -166.09M | -39.14% |
| Dec 31, 2022 | 424.30M | 133.35M | 45.83% |
| Dec 31, 2021 | 290.95M | 6.03M | 2.11% |
| Dec 31, 2020 | 284.93M | 29.45M | 11.53% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Zhejiang East Asia Pharmaceutical | 831.56M |
| Guiyang Xintian Pharmaceutical | 755.34M |
| Jilin Jian Yisheng Pharmaceutical | 639.10M |
| Hubei Goto Biopharm | 626.28M |
| Tiansheng Pharmaceutical Group | 516.17M |
| Jiangsu Sihuan Bioengineering | 341.90M |
| Sailong Pharmaceutical Group | 244.84M |
| Jiangsu CoWin Biotech | 167.17M |